2022
DOI: 10.3390/cancers14194643
|View full text |Cite
|
Sign up to set email alerts
|

Concomitant Use of Sulforaphane Enhances Antitumor Efficacy of Sunitinib in Renal Cell Carcinoma In Vitro

Abstract: Chronic treatment of renal cell carcinoma (RCC) with the tyrosine kinase inhibitor sunitinib (ST) inevitably induces resistance and tumor re-activation. This study investigated whether adding the natural compound sulforaphane (SFN) with its anti-cancer properties could improve ST efficacy in vitro. The RCC cell lines A498, Caki1, KTCTL26, and 786O were exposed to ST, SFN, or both (dual therapy, DT) before (short-term exposure) and during ST-resistance buildup (long-term 8-week exposure). Tumor growth, prolifer… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
3
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(3 citation statements)
references
References 32 publications
0
3
0
Order By: Relevance
“…Short-term SFN application reduced cell numbers across diverse lines, sensitizing RCC cells to ST. Long-term SFN use exhibited greater effectiveness, particularly in 786O cells, where the ST-SFN combination outperformed SFN alone [74]. These findings underscore SFN's significant anticancer potential in countering tumor reactivation and resistance, propelling further clinical research.…”
Section: Sfn As An Anticancer Agentmentioning
confidence: 76%
“…Short-term SFN application reduced cell numbers across diverse lines, sensitizing RCC cells to ST. Long-term SFN use exhibited greater effectiveness, particularly in 786O cells, where the ST-SFN combination outperformed SFN alone [74]. These findings underscore SFN's significant anticancer potential in countering tumor reactivation and resistance, propelling further clinical research.…”
Section: Sfn As An Anticancer Agentmentioning
confidence: 76%
“…In addition, SFN augmented the anti-cancer efficacy of sunitinib in renal cell carcinoma (RCC) by diminishing cell growth and proliferation. The combination treatment induced G2/M phase arrest by suppressing cyclin A, cyclin B, CDK1, p-CDK1, CDK2, and p-CDK2 in RCC cell lines [123].…”
Section: Other Cancersmentioning
confidence: 94%
“…Due to their effects on both plants and humans, GSLs are a current biology research focus [4][5][6][7][8][9]. Indeed, rapeseed breeders focus on harmful GSLs in rapeseed cakes, vegetable breeders are more interested in anticancer GSLs that are beneficial to humans, and medical scientists focus on GSLs that are inhibitory to tumor cells [10][11][12][13][14]. Sulforaphane, a secondary metabolite, relieves neuropathic pain caused by chemotherapy and inhibits prostate, colon, breast, pancreatic, and bladder cancers [15][16][17][18][19].…”
Section: Introductionmentioning
confidence: 99%